Buso G, Corvini F, Fusco E, Messina M, Cherubini F, Laera N
J Clin Med. 2024; 13(14).
PMID: 39064294
PMC: 11278074.
DOI: 10.3390/jcm13144255.
Legrand A, Guery C, Faugeroux J, Fontaine E, Beugnon C, Gianfermi A
PLoS Genet. 2022; 18(3):e1010059.
PMID: 35245290
PMC: 8926273.
DOI: 10.1371/journal.pgen.1010059.
Bouchard J, Shepherd G, Hoffman R, Gosselin S, Roberts D, Li Y
Crit Care. 2021; 25(1):201.
PMID: 34112223
PMC: 8194226.
DOI: 10.1186/s13054-021-03585-7.
Ghosh A, Brindisi M
J Med Chem. 2019; 63(6):2751-2788.
PMID: 31789518
PMC: 7266097.
DOI: 10.1021/acs.jmedchem.9b01541.
van Nuland M, Rosing H, Huitema A, Beijnen J
Clin Pharmacokinet. 2019; 58(10):1221-1236.
PMID: 31030372
DOI: 10.1007/s40262-019-00769-x.
Celiprolol: A Unique Selective Adrenoceptor Modulator.
Nawarskas J, Cheng-Lai A, Frishman W
Cardiol Rev. 2017; 25(5):247-253.
PMID: 28742547
PMC: 5549637.
DOI: 10.1097/CRD.0000000000000159.
Model analysis of the concentration-dependent permeability of P-gp substrates.
Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S
Pharm Res. 2010; 27(3):442-6.
PMID: 20135207
DOI: 10.1007/s11095-009-0026-9.
Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs.
Lipka E, Lee I, Langguth P, Spahn-Langguth H, Mutschler E, Amidon G
J Pharmacokinet Biopharm. 1995; 23(3):267-86.
PMID: 8834196
DOI: 10.1007/BF02354285.
Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.
Dunn C, Spencer C
Drugs Aging. 1995; 7(5):394-411.
PMID: 8573993
DOI: 10.2165/00002512-199507050-00006.
The contribution of intestinal secretion to the dose-dependent absorption of celiprolol.
Kuo S, Whitby B, Artursson P, Ziemniak J
Pharm Res. 1994; 11(5):648-53.
PMID: 8058631
DOI: 10.1023/a:1018959809352.
A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.
Kendall M, Rajman I
Drug Saf. 1994; 10(3):220-32.
PMID: 7913813
DOI: 10.2165/00002018-199410030-00004.
Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein.
Karlsson J, Kuo S, ZIEMNIAK J, Artursson P
Br J Pharmacol. 1993; 110(3):1009-16.
PMID: 7905337
PMC: 2175785.
DOI: 10.1111/j.1476-5381.1993.tb13914.x.
Comparison of the antihypertensive effects of celiprolol and acebutolol.
Terziivanov D, Vlahov V, Belovezhdov N, Gerova Z
Eur J Clin Pharmacol. 1988; 34(2):125-8.
PMID: 2968268
DOI: 10.1007/BF00614547.
Hemodynamic effects of celiprolol at rest and during exercise; a comparison with enalapril.
Ghiringhelli S, Cozzi E, Tsialtas D
Cardiovasc Drugs Ther. 1988; 2(2):211-8.
PMID: 2908720
DOI: 10.1007/BF00051236.
Importance of ancillary properties of beta blockers in angina: a study of celiprolol and atenolol.
McLenachan J, Wilson J, Dargie H
Br Heart J. 1988; 59(6):685-9.
PMID: 2899439
PMC: 1276876.
DOI: 10.1136/hrt.59.6.685.
Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris.
Riddell J, Shanks R, Brogden R
Drugs. 1987; 34(4):438-58.
PMID: 2890513
DOI: 10.2165/00003495-198734040-00002.
Comparison of the cardiovascular and pulmonary effects of oral celiprolol, propranolol and placebo in normal volunteers.
Busst C, Bush A
Br J Clin Pharmacol. 1989; 27(4):405-10.
PMID: 2566321
PMC: 1379717.
DOI: 10.1111/j.1365-2125.1989.tb05386.x.
Effect of celiprolol on large and small arteries of the forearm circulation in hypertensive patients.
ROMAN O, Meza N, Klenner C
Cardiovasc Drugs Ther. 1990; 4(3):745-9.
PMID: 2150174
DOI: 10.1007/BF01856564.
Comparative enantioselective pharmacokinetic studies of celiprolol in healthy volunteers and patients with impaired renal function.
Hartmann C, Frolich M, Krauss D, Spahn-Langguth H, Knauf H, Mutschler E
Eur J Clin Pharmacol. 1990; 39(6):573-6.
PMID: 1982763
DOI: 10.1007/BF00316098.
Evaluation of celiprolol, a new cardioselective beta 1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly.
Lamon K
Cardiovasc Drugs Ther. 1991; 4 Suppl 6:1291-5.
PMID: 1672605
DOI: 10.1007/BF00114236.
